1. Home
  2. ADIL

as 05-28-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

Founded: 2010 Country:
United States
United States
Employees: N/A City: CHARLOTTESVILLE
Market Cap: 6.0M IPO Year: 2018
Target Price: $150.00 AVG Volume (30 days): 4.6M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.15 EPS Growth: N/A
52 Week Low/High: $0.77 - $14.00 Next Earning Date: 05-14-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: